跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 28 条关于
“PFIC2”
全部
28
临床试验
17
药物
1
机构
0
资讯
10
去年
Odevixibat Demonstrates Favorable Safety Profile in Pediatric PFIC Patients
2年前
Maralixibat Demonstrates Efficacy in Treating Pruritus and Reducing Bile Acids in PFIC Patients
12个月前
Ipsen's Bylvay Receives Japanese Approval for Rare Liver Disease PFIC, Offering First Non-Surgical Treatment Option
去年
Rectify Pharma's Novel Dual-Targeted PFM Shows Promise for Hepatobiliary Diseases at EASL 2025
2年前
FDA Expands Livmarli Approval for PFIC Patients Aged 12 Months and Older
3天前
Japan Approves Buphenyl (Sodium Phenylbutyrate) for PFIC Types 1 and 2 After 20-Year Research Effort
去年
Odevixibat Demonstrates Sustained Improvement in Itch and Bile Acid Levels in PFIC and ALGS Patients
去年
Bylvay Demonstrates Sustained Improvement in Itch and Bile Acid Levels in PFIC and ALGS Patients
去年
Odevixibat Demonstrates Sustained Improvement in Pruritus and Bile Acid Levels in PFIC and ALGS Patients
去年
Bylvay (Odevixibat) Shows Sustained Improvement in Itch and Bile Acid Levels in PFIC and ALGS Patients
